Skip to main content
. 2022 Nov 1;132(21):e161858. doi: 10.1172/JCI161858

Figure 5. Clinical outcomes from ARSI trials and emergence of neuroendocrine markers.

Figure 5

(A) Kaplan-Meier curves show that patients with expression of neuroendocrine markers, even with preserved AR target gene expression, have worse overall survival (OS) in 2 phase II adenocarcinoma ARSI (enzalutamide and abiraterone) clinical trials. P is calculated via log-rank test. (B) Kaplan-Meier curves show that patients with expression of neuroendocrine markers, even with preserved AR target gene expression, have worse time to treatment failure (TTF) in a phase II adenocarcinoma ARSI (seviteronel) clinical trial. P values were calculated via log-rank test.